NextCure, Inc. (NXTC:NASDAQ) closed at $5.42 on October 20, 2026, down 4.41% on the day. The stock trades 65.6% below its 52-week high of $15.74 and 249.7% above its 52-week low of $1.55. Over the past year, it lost 47.6%. NextCure, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 17, 2025, NXTC closed higher on 118 days (47%). Its best day was July 14, 2026 (+201.83%) and its worst was June 1, 2026 (-45.48%). The stock moved 10% or more in a single session 35 times. It opened at least 5% above the previous day's high 3 times.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is a immunomedicine against a immunomodulatory receptor called Siglec-15, or S15.
Find more stocks like NXTC with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.